BIOMAT Database Logo BIOMAT Database Logo

[Changes in thrombocyte-vascular hemostasis and cyclic nucleotide levels after anti-arrhythmia therapy in patients with ischemic heart disease]. 1989

V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov

Platelet-vascular hemostasis and cyclic nucleotide levels as well as the effects of mexitil, ritmilen and prolecofen on those were examined in 58 coronary patients with various heart rhythm disorders. The patients showed considerably increased platelet activity, low prostacyclin level and high thromboxane and cyclic nucleotides levels, particularly in patients with high-grade ventricular extrasystoles. Mexitil did not essentially affect the parameters in question. Ritmilen produced a significant increase in 6-keto-PGF1 alpha and a decrease of platelet activity. In prolecofen-treated patients, platelet activity decreased significantly, cAMP and cGMP dropped while the cAMP/cGMP ratio went up; prostacyclin and thromboxane changes were not significant. This may be a mechanism of prolecofen's antiarrhythmic action.

UI MeSH Term Description Entries
D008297 Male Males
D008801 Mexiletine Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. KO-1173,KO1173,KOE-1173,Mexiletene,Mexiletine Hydrochloride,Mexitil,Mexitil PL,Mexityl,Novo-Mexiletine,KO 1173,KOE 1173,KOE1173,Novo Mexiletine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009712 Nucleotides, Cyclic Cyclic Nucleotide,Cyclic Nucleotides,Nucleotide, Cyclic
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011405 Propafenone An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. Apo-Propafenone,Arythmol,Baxarytmon,Cuxafenon,Fenoprain,Jutanorm,Nistaken,Norfenon,Pintoform,Prolecofen,Propafenon AL,Propafenon Hexal,Propafenon Minden,Propafenone Hydrochloride,Propafenone Hydrochloride, (R)-Isomer,Propafenone Hydrochloride, (S)-Isomer,Propafenone, (+-)-Isomer,Propafenone, (R)-Isomer,Propafenone, (S)-Isomer,Propamerck,Rythmol,Rytmo-Puren,Rytmogenat,Rytmonorm,SA-79,Hydrochloride, Propafenone,SA 79,SA79
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004206 Disopyramide A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. Diisopyramide,Disopyramide Monohydrochloride,Disopyramide Phosphate,Disopyramide Phosphate (1:1),Disopyramide Phosphate (1:1), (+-)-Isomer,Disopyramide Phosphate (1:1), (R)-Isomer,Disopyramide Phosphate (1:1), (S)-Isomer,Disopyramide, (+-)-Isomer,Disopyramide, (R)-Isomer,Disopyramide, (S)-Isomer,Disopyramide, D-Tartrate (1:1), (S)-Isomer,Disopyramide, L-Tartrate (1:1), (R)-Isomer,Disopyramide, L-Tartrate (1:1), (S)-Isomer,Disopyramide, L-Tartrate (1:2), (+-)-Isomer,Disopyramide, L-Tartrate, (S)-isomer,Norpace,Palpitin,Palpitine,Rhythmodan,Ritmilen,Rythmilen,SC-13957,SC 13957,SC13957
D005260 Female Females

Related Publications

V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Effect of ischemic heart disease risk factors on plasma and vascular-thrombocyte hemostasis].
August 1981, Kardiologiia,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Changes in the platelet-vascular system of hemostasis in patients with ischemic heart disease and hypertension after the treatment].
October 1989, Kardiologiia,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Changes in hemostasis in ischemic heart disease].
March 1993, Bratislavske lekarske listy,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Thrombocyte aggregation in patients with ischemic heart disease and hypertension].
July 1971, Klinicheskaia meditsina,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Characteristics psychoemotional and neurohumoral changes during arrhythmia in patients with ischemic heart disease].
January 1983, Terapevticheskii arkhiv,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Changes in thrombocyte-vascular hemostasis in the early postoperative period].
January 1982, Anesteziologiia i reanimatologiia,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Thrombocytic-vascular hemostasis at rest and under physical loading in patients with ischemic heart disease].
January 1993, Kardiologiia,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
Changes in histamine and cyclic nucleotide levels after bronchoprovocation in patients with extrinsic asthma.
January 1978, Scandinavian journal of respiratory diseases,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Changes in plasma lipid and apoprotein levels in patients with ischemic heart disease after hemosorption].
January 1992, Kardiologiia,
V A Liusov, and V A Dudaev, and V V Borodkin, and A V Rudakov
[Thrombocyte adhesiveness in ischemic heart disease].
August 1972, Kardiologiia,
Copied contents to your clipboard!